NCI-H2023Homo sapiens (Human)Cancer cell line
Also known as: NCIH2023, H-2023, H2023
Quick Overview
Human cancer cell line with potential applications in cancer research and drug development.
Detailed Summary
Basic Information
Database ID | CVCL_1515 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
Age | 26 |
---|---|
Age Category | Adult |
Sex | Male |
Race | caucasian |
Disease Information
Disease | Lung adenocarcinoma |
---|---|
Lineage | Lung |
Subtype | Lung Adenocarcinoma |
OncoTree Code | LUAD |
DepMap Information
Source Type | ATCC |
---|---|
Source ID | ACH-000781_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | TP53 | p.Ser240Arg (c.720T>A) | Homozygous | - | Unknown, Unknown |
MutationSimple | SMARCA4 | p.Ser828Profs*3 (c.2481delC) (p.Ala826fs) (c.2477delC) | Heterozygous | - | Unknown, Unknown |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Cell 131:1190-1203(2007).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Gazdar A.F.
Oncogene 7:171-180(1992).